Sanford Health | Clinical Research Department

Research site

(Unclaimed)

Location

1305 W. 18th Street, Sioux Falls, South Dakota, United States of America

Site insights

Top conditions

Top treatments

Macitentan

Milademetan

Cenicriviroc

Alcohol

Osimertinib

Morphine

Ompenaclid

Methadone

Cyclosporine

CB-839

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

14 of 55 total trials

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermed...

Enrolling

Myelofibrosis

Drug: Imetelstat

Drug: Best Available Therapy (BAT)

A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

This is an open label Phase 1b/2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or in combination with ultralow dose gemcitabine...

Enrolling

Endometrial Adenocarcinoma

Urothelial Carcinoma

Drug: ACR-368

Diagnostic Test: OncoSignature

A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions (PAPILLON)

The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in...

Active, not recruiting

Carcinoma, Non-Small-Cell Lung

Drug: Pemetrexed

Drug: Amivantamab

A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation

This is a multi-center, open-label study to investigate the safety, efficacy and pharmacokinetics of REC-4881 (12 mg PO daily doses) for the treatmen...

Enrolling

Solid Tumor

APC Gene Mutation

Drug: REC-4881

A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer

This is a Phase 1 study currently evaluating PO administered ompenaclid in combination with FOLFIRI and bevacizumab in patients with advanced (i.e.,...

Enrolling

Colorectal Carcinoma

KRAS Mutation-Related Tumors

Drug: Bevacizumab

Drug: ompenaclid

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

This study was to assess the antitumor activity, safety, tolerability, and pharmacokinetics (PK) of the Mesenchymal-epithelial Transition Factor (MET...

Active, not recruiting

Non-small Cell Lung Cancer

Drug: Tepotinib

Drug: Osimertinib

BlueWind RENOVA iStim™ System for the Treatment of OAB (OASIS)

The OASIS study is prospective, interventional, multi-center study to evaluate the safety and efficacy of the BlueWind RENOVA iStim™ implantable tibi...

Enrolling

Treatment of Patients Suffering From Overactive Bladder (OAB)

Device: RENOVA iStim™ System

Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) (A DUE)

Combination therapy in pulmonary arterial hypertension (PAH) has been the subject of active investigation for more than a decade, with the benefit of...

Active, not recruiting

Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)

Drug: Placebo tadalafil

Drug: Macitentan 10 mg

Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control at Home

The purpose of this study is to evaluate the safety and effectiveness of the Hybrid Closed Loop system (HCL) in adult and pediatric patients with typ...

Enrolling

Type 1 Diabetes

Device: Subject's Current Diabetes Therapy

Device: 670G and 770G Insulin Pump

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic in...

Active, not recruiting

Solid Tumor

Malignant Neoplasm

Drug: nab-sirolimus

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

Evaluate the safety and tolerability of AMG 509 in adult participants and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2...

Enrolling

Prostate Cancer

Drug: Abiraterone

Drug: Enzalutamide

Study of IMNN-001 (also Known As GEN-1) with NACT for Treatment of Ovarian Cancer (OVATION 2)

This is a randomized, open label, multicenter trial to evaluate the safety, dosing, efficacy and biological activity of intraperitoneal IMNN-001 plus...

Active, not recruiting

Primary Peritoneal Cancer

Epithelial Ovarian Cancer

Biological: IMNN-001

Drug: Carboplatin

Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors

This is a first-in-human, phase 1, open-label, dose-escalation study of STI-6643 administered by intravenous infusion in subjects with a relapsed/ref...

Enrolling

Solid Tumor

Refractory Tumor

Biological: STI-6643

Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis

This study is a Phase 2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple asce...

Active, not recruiting

Primary Biliary Cholangitis

Drug: CNP-104

Drug: Placebo